AXL is upregulated in many cancers being resistant to first‐line treatments, and clinical trials with AXL inhibitors are ongoing in several cancers, including triple‐negative breast cancer (TNBC) and non‐small‐cell lung cancer (NSCLC) (Myers et al., 2016). Here, AXL is linked to non-small cell lung carcinoma.